HAE · Haemonetics Corp · Insider Trading

The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

This number includes unvested RSUs previously reported.

Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

This number includes unvested RSUs previously reported.

Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

This number includes unvested RSUs previously reported as well as 415 shares acquired by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026.

The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

This number includes unvested RSUs previously reported.

Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

This number includes unvested RSUs previously reported.

The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

This number includes unvested RSUs previously reported.

Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

This number includes unvested RSUs previously reported as well as 497 shares purchased by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026.

The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

This number includes unvested RSUs previously reported.

The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

This number includes unvested RSUs previously reported as well as 415 shares acquired by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026.

The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

This number includes unvested RSUs previously reported.

The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

This number includes unvested RSUs previously reported as well as 497 shares purchased by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026.

The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

This number includes unvested RSUs previously reported, 139 shares acquired by the reporting person on October 31, 2025 under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time, the "ESPP") and 119 shares acquired by the reporting person on April 30, 2026 under the ESPP.

Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

This number includes unvested RSUs previously reported, 139 shares acquired by the reporting person on October 31, 2025 under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time, the "ESPP") and 119 shares acquired by the reporting person on April 30, 2026 under the ESPP.

Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

This number includes unvested RSUs previously reported.

Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

This number includes unvested RSUs previously reported.

Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

This number includes unvested RSUs previously reported.

Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

This number includes unvested RSUs previously reported.

This number includes unvested restricted stock units previously reported.

Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

This number includes unvested RSUs previously reported as well as 24 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on October 31, 2025.

Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

This number includes unvested RSUs previously reported.

The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. Two-thirds of the RSUs vest in two equal annual installments beginning on the first anniversary of the date of grant and one-third of the RSUs vests based on the Issuer's common stock price at the end of a two-year performance period.

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

This number includes unvested RSUs previously reported.

The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. Two-thirds of the RSUs vest in two equal annual installments beginning on the first anniversary of the date of grant and one-third of the RSUs vests based on the Issuer's common stock price at the end of a two-year performance period.

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

This number includes unvested RSUs previously reported.

Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.

This number includes unvested restricted stock units ("RSUs") previously reported.

Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.

This number includes unvested restricted stock units ("RSUs") previously reported.

Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 16, 2022, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 16, 2022 to May 15, 2025, as certified by the Compensation Committee of the Board of Directors on May 30, 2025.

This number includes unvested restricted stock units ("RSUs") previously reported.

Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.

This number includes unvested restricted stock units ("RSUs") previously reported.

Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 16, 2022, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 16, 2022 to May 15, 2025, as certified by the Compensation Committee of the Board of Directors on May 30, 2025.

This number includes unvested restricted stock units ("RSUs") previously reported.

Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.

This number includes unvested restricted stock units ("RSUs") previously reported.

Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 16, 2022, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 16, 2022 to May 15, 2025, as certified by the Compensation Committee of the Board of Directors on May 30, 2025.

This number includes unvested restricted stock units ("RSUs") previously reported.

Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 16, 2022, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 16, 2022 to May 15, 2025, as certified by the Compensation Committee of the Board of Directors on May 30, 2025.

This number includes unvested restricted stock units ("RSUs") previously reported.

Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

This number includes unvested RSUs previously reported as well as 328 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2025.

Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

This number includes unvested RSUs previously reported.

The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

This number includes unvested RSUs previously reported.